WHO global digital library - online access to WHO published material

IRIS is experiencing internal errors due to web traffic. Please try again.

Recent Submissions

Application of the World Health Organization Programmatic Assessment Tool for Risk of Measles Virus Transmission-Lessons Learned from a Measles Outbreak in Senegal
Oumar Ba, Ibrahim;Badiane, Ousseynou;Masresha, Balcha G;Nicholson, Jennifer;Goodson, James L;Fall, Amadou;Harris, Jennifer B;Diallo, Aliou;Lam, Eugene

The World Health Organization (WHO) African Region set a goal for regional measles elimination by 2020; however, regional measles incidence was 125/1,000,000 in 2012. To support elimination efforts, the WHO and U.S. Centers for Disease Control and Prevention developed a tool to assess performance of measles control activities and identify high-risk areas at the subnational level. The tool uses routinely collected data to generate district-level risk scores across four categories: population i...

Paracervical block as pain treatment during second-trimester medical termination of pregnancy: an RCT with bupivacaine versus sodium chloride
Christensson, K;Gemzell-Danielsson, K;Benson, L;Andersson, I-M

Can paracervical block (PCB) administered before the onset of pain decrease women's pain experience during second-trimester medical termination of pregnancy (MToP)?There were no clinically significant differences between groups receiving PCB with bupivacaine or saline with regard to the highest and lowest pain intensity, morphine consumption or induction-to abortion interval.The most common side effect of misoprostol is pain; nevertheless, there are sparse studies in pain and pain treatment d...

Overlooking the importance of immunoassays - Authors' reply
Johnson, Joshua C;Norwood, David A;Honko, Anna N;Kuhn, Jens H;Hill, Charles E;Griffiths, Anthony;Hewlett, Angela;Sprecher, Armand;Jahrling, Peter B;Kraft, Colleen S;Formenty, Pierre;Palacios, Gustavo F;Ariën, Kevin K;Kobinger, Gary;Sabeti, Pardis;Colebunders, Robert;Cnops, Lieselotte;van Griensven, Johan;Bausch, Daniel G

Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant
Hubacher, David;Landoulsi, Sihem;Brache, Vivian;Habib, Ndema;Bahamondes, Luis;Ali, Moazzam;Akin, Ayse

Is it possible to extend the use of the 3-year one-rod etonogestrel (ENG)-releasing subdermal contraceptive implant to 5 years?The extended use of the one-rod ENG-releasing subdermal contraceptive implant showed 100% efficacy in years 4 and 5.The initial regulated trials on the ENG-releasing subdermal contraceptive implant conducted in the 1990 s were designed to measure cumulative 3-year efficacy. The ENG-implant has both well established safety and efficacy for up to 3 years. Pharmacokineti...

Weekly Epidemiological Record, vol. 91, 39 [full issue]
World Health Organization